

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: E21/22 - Hormones 2

Deadline: 08.02.2022

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]						Comparability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(393) C-peptide					11							10	9	90%
Samples and groups	[pmol/L]													
Sample A		378	92	24	11							10	9	90%
Other					11	0						10		
							3x 4/1, 1x 4/29, 4x 4/60, 3x 4/179							
Sample B		162	42	26	11							10	9	90%
Other					11	0						10		
							3x 4/1, 1x 4/29, 4x 4/60, 3x 4/179							
(193) Ferritin					16							16	14	88%
Samples and groups	[µg/L]													
Sample A		132	34	26	16							16	14	88%
Other					16	0						16		
							3x 4/1, 1x 4/12, 4x 4/60, 1x 4/149, 4x 4/179, 2x 6/58, 1x 6/60							
Sample B		38,0	9,5	25	16							16	15	94%
Other					16	0						16		
							3x 4/1, 1x 4/12, 4x 4/60, 1x 4/149, 4x 4/179, 2x 6/58, 1x 6/60							
(321) FSH					13							12	12	100%
Samples and groups	[U/L]													
Sample A		8,39	0,54	6,4	13							12	12	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		8,24	0,15	1,8	6	0	CVPG	8,61	0,048	15%	7,31	9,91	6	
(60) Roche														
Other					7	0						6		
							1x 3/25, 3x 4/1, 2x 4/12, 1x 4/149							
Sample B		14,9	0,79	5,3	13							12	12	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		14,5	0,53	3,6	6	0	CVPG	14,9	0,078	15%	12,6	17,2	6	
(60) Roche														
Other					7	0						6		
							1x 3/25, 3x 4/1, 2x 4/12, 1x 4/149							
(328) hGH					7							7	7	100%
Samples and groups	[mU/L]													
Sample A		39,8	1,6	3,9	7							7	7	100%
Other					7	0						7		
							2x 4/12, 4x 4/29, 1x 4/60							
Sample B		2,73	0,80	29	7							7	7	100%
Other					7	0						7		
							2x 4/12, 4x 4/29, 1x 4/60							
(329) IGF-1					6							6	5	83%
Samples and groups	[µg/L]													
Sample A		613	130	21	6							6	5	83%
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		647	76	12	5	0	CVPG	689	17	22%	537	841	5	
(29) Siemens (Immulite)														
Other					1	0						1		
							1x 4/60							
Sample B		125	33	26	6							6	5	83%
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		140	11	8,0	5	0	CVPG	146	2,5	22%	113	179	5	
(29) Siemens (Immulite)														
Other					1	0						1		
							1x 4/60							
(392) IGF-BP3					2							2	2	100%
Samples and groups	[µg/L]													
Sample A		3330	470	14	2							2	2	100%
Other					2	0						2		
							1x 4/29, 1x 4/60							
Sample B		3550	550	16	2							2	2	100%
Other					2	0						2		
							1x 4/29, 1x 4/60							
(325) Insulin					8							8	8	100%
Samples and groups	[mU/L]													
Sample A		73,8	16	21	8							8	8	100%
Other					8	0						8		
							2x 4/1, 3x 4/60, 3x 4/179							
Sample B		16,8	2,2	13	8							8	8	100%
Other					8	0						8		
							2x 4/1, 3x 4/60, 3x 4/179							
(326) Folate					16							0		
Samples and groups	[nmol/L]													
Sample A		9,06	2,0	22	16							16	15	94%
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		7,95	0,37	4,7	7	0	CVPG	7,88	0,15	27%	5,75	10,1	7	
(60) Roche														

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: E21/22 - Hormones 2

Deadline: 08.02.2022

Test	[unit]						Comparability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(326) Folate					16							0		
Samples and groups	[nmol/L]													
Sample A		9,06	2,0	22	16							16	15	94%
Other					9	0						9		
							4x 4/1, 1x 4/12, 1x 4/149, 3x 4/179							
Sample B		50,5	7,0	14	16							0		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		45,5	0,21	0,46	7	1	CVPG	45,4	0,0047	27%	33,1	57,7	0	
Other					9	2						0		
							4x 4/1, 1x 4/12, 1x 4/149, 3x 4/179							
(320) LH					13							12	12	100%
Samples and groups	[U/L]													
Sample A		30,3	5,6	19	13							12	12	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		33,9	0,82	2,4	6	0	CVPG	34,1	0,19	15%	28,9	39,3	6	
Other					7	0						6		
							1x 3/25, 3x 4/1, 2x 4/12, 1x 4/149							
Sample B		8,26	2,0	25	13							12	12	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		10,0	0,42	4,2	6	0	CVPG	9,86	0,061	15%	8,38	11,4	6	
Other					7	0						6		
							1x 3/25, 3x 4/1, 2x 4/12, 1x 4/149							
(405) Parathyroid hormone (PTH)					14							14	13	93%
Samples and groups	[pmol/L]													
Sample A		1,05	0,13	12	14							14	14	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		1,05	0,088	8,4	12	0	CVPG	1,04	0,015	±0,28	0,764	1,32	12	
Other					2	0						2		
							1x 4/1, 1x 4/12							
Sample B		0,546	0,11	20	14							14	13	93%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		0,557	0,10	18	12	0	CVPG	0,586	0,014	±0,276	0,31	0,862	12	
Other					2	1						2		
							1x 4/1, 1x 4/12							
(322) Prolactin					13							12	12	100%
Samples and groups	[mU/L]													
Sample A		162	29	18	13							12	12	100%
Other					13	0						12		
							1x 3/25, 2x 4/1, 2x 4/12, 4x 4/60, 1x 4/149, 3x 4/179							
Sample B		194	36	18	13							12	12	100%
Other					13	0						12		
							1x 3/25, 2x 4/1, 2x 4/12, 4x 4/60, 1x 4/149, 3x 4/179							
(390) Renin					5							5	2	40%
Samples and groups	[ng/L]													
Sample A		52,6	9,7	18	5							5	2	40%
Other					5	0						5		
							1x 1/185, 4x 4/164							
Sample B		74,0	18	25	5							5	3	60%
Other					5	0						5		
							1x 1/185, 4x 4/164							
(394) SHBG					9							9	9	100%
Samples and groups	[nmol/L]													
Sample A		34,0	1,5	4,3	9							9	9	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		34,0	1,5	4,3	6	0	CVPG	32,7	0,24	20%	26,1	39,3	6	
Other					3	0						3		
							1x 4/1, 1x 4/12, 1x 4/29							
Sample B		64,1	3,3	5,2	9							9	9	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		64,4	2,9	4,4	6	0	CVPG	62,3	0,44	20%	49,8	74,8	6	
Other					3	0						3		
							1x 4/1, 1x 4/12, 1x 4/29							
(327) Vitamin B12					16							16	15	94%
Samples and groups	[pmol/L]													
Sample A		682	64	9,3	16							16	16	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		702	50	7,2	7	0	CVPG	675	4,4	20%	540	810	7	
Other					9	0						9		
							4x 4/1, 1x 4/12, 1x 4/149, 3x 4/179							
Sample B		943	120	12	16							16	15	94%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		916	21	2,3	7	0	CVPG	919	5,6	20%	735	1110	7	
Other					9	0						9		
							4x 4/1, 1x 4/12, 1x 4/149, 3x 4/179							

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: E21/22 - Hormones 2

Deadline: 08.02.2022

Test	[unit]						Comparability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(319) Vitamin B12 (active)					5							0		
----- Samples and groups -----	[pmol/L]													
Sample A		148	3,0	2,0	5							0		
Other					5	0						0		
							1x 4/1, 3x 4/60, 1x 4/179							
Sample B		148	3,0	2,0	5							0		
Other					5	0						0		
							1x 4/1, 3x 4/60, 1x 4/179							
st_kn_p							End of report							Printed: 16.02.2022